POLITICS

Bengaluru Counterfeit Cancer Drug Ring Linked to Over 90 Hospitals, Police Say

By Open Vaartha Desk · 2026-09-13

What happened

A police special investigation team has arrested a pharmacy owner after uncovering a network that allegedly repackaged expired and fake cancer medicines, supplying them to more than 90 Bengaluru hospitals and clinics. The racket, valued at up to ₹5 crore, raises urgent questions about drug verification in India’s health system. A Bengaluru pharmacy owner was arrested after investigators linked a counterfeit cancer‑drug network to over 90 hospitals, exposing a major public‑health risk.

TL;DR

A Bengaluru pharmacy owner was arrested after investigators linked a counterfeit cancer‑drug network to over 90 hospitals, exposing a major public‑health risk.

Key points

Veeresh Kumar Jain, owner of Krupa Healthcare, was arrested by the Bengaluru Police SIT
The alleged racket repackaged expired medicines and sold counterfeit cancer drugs at roughly 50% discount
Seized counterfeit stock from an earlier Bidadi raid was valued at ₹4.9–5 crore
Investigators suspect the fake medicines reached more than 90 hospitals and clinics in Bengaluru
Authorities are pursuing a key figure, R Prashant, believed to be in Azerbaijan

The Bengaluru Police Special Investigation Team (SIT), working alongside the Drugs Control Department, has taken the owner of Krupa Healthcare, Veeresh Kumar Jain, into custody. Jain’s pharmacy, located near Minerva Circle, was raided and a large cache of suspected counterfeit medicines was seized.Investigators say the alleged network dealt in cancer drugs, other life‑saving medicines and ICU injections, moving them through the city’s medical supply chain to more than 90 hospitals and clinics. While the exact number of institutions that knowingly purchased the fake products remains under investigation, the scale of the operation has prompted a public‑health alarm.How the racket operated<ul><li>The scheme reportedly sourced low‑cost or outright spurious medicines, then repackaged or relabelled them with counterfeit branding that mimicked major pharmaceutical companies.</li><li>Expired stock was allegedly given a new identity, with counterfeit labels and packaging used to disguise the products.</li><li>Prices were slashed by roughly 50 percent, a discount that made the drugs attractive to buyers and facilitated rapid movement through the supply chain.</li></ul>An earlier raid near Bidadi in August uncovered a trove of expired medicines, counterfeit labels, packaging material and equipment used for filling injections. The seized items were valued at approximately ₹4.9–5 crore.Why the case matters Cancer treatment hinges on precise dosages and specific active ingredients. A counterfeit or sub‑standard drug can render a chemotherapy regimen ineffective, expose patients to harmful substances, or delay critical care. Patients place their trust in hospitals, pharmacies and the labels on vials; any breach of that trust can have life‑threatening consequences.Investigative focus The SIT is now combing through batch numbers, transaction records and seized documents to answer a series of pressing questions: which hospitals and pharmacies received the suspected medicines; which specific batches were involved; whether the drugs were actually administered; how long the network operated; who manufactured or sourced the counterfeit products; who produced the fake packaging; and whether any insiders in the legitimate supply chain facilitated the distribution.Broader network The investigation began after the August Bidadi raid, prompting the Karnataka Food Safety and Drugs Administration to form an SIT that includes police and drug‑control officials. Searches have extended to multiple locations across several states. Authorities are also pursuing a key alleged figure, R Prashant, who is reported to be in Azerbaijan, and several other arrests have already been made, suggesting the operation was far larger than a single pharmacy.Systemic questions for hospitals The case forces a re‑examination of procurement practices: Are batch numbers verified before purchase? Are suppliers thoroughly vetted? Do hospitals routinely audit invoices and distribution records? And when a drug is offered at a price dramatically below market rates, are red‑flags raised?Patient safety and transparency While the presence of counterfeit medicines in the supply chain does not automatically mean every hospital knowingly participated or that every patient was harmed, authorities must act swiftly to identify affected batches, notify any exposed patients, and provide clear communication to prevent panic.India’s pharmaceutical landscape India, home to one of the world’s largest pharmaceutical industries, supplies millions of doses daily. The counterfeit‑drug problem therefore carries heightened risk, especially for oncology patients for whom a fake injection can mean a missed or ineffective treatment.The SIT’s mandate now extends beyond arresting a pharmacy owner; it must trace every supplier, every batch, and every institution that received the suspect medicines, and prosecute all proven participants. In a sector where authenticity can be a matter of life and death, the stakes could not be higher.